Program Description
Precision medicine relies
heavily on the accurate characterization of tumor biomarkers. The human
epidermal growth factor receptor 2 (HER2), encoded by the ERBB2 gene, is a
critical oncogenic driver across multiple tumor types, and its status dictates
eligibility for targeted therapies; however, reliably determining HER2 status
presents substantial clinical challenges. This program will analyze the
pathobiology of HER2 and address the difficulties in its assessment across
various tumor types beyond breast and gastric cancers. Limitations of current
testing methodologies (IHC, ISH, NGS) and the crucial, often inconsistent,
interpretation of results, particularly for emerging categories like HER2-low
and HER2 ultra-low expression, as well as ERBB2 mutations, will be explored.
This webinar will center on strategies that oncology pharmacists can implement
to ensure the effective use of biomarker findings, highlighting their evolving
roles in precision medicine through institutional-based strategies for treatment
optimization, patient education, and interdisciplinary collaboration.
Target Audience: Health System Pharmacist, Oncology
Pharmacist
Type of Activity: Application
Release date: January
26, 2026
Expiration date: January
26, 2027
Learner
level: Intermediate
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Analyze the pathobiology of HER2 in tumor growth and the significance of HER2 alterations
- Apply HER2 testing methodologies, including guideline-recommended assays specific to various tumor types
- Express the evolving role of pharmacists in precision medicine, including overcoming challenges in utilizing biomarker findings
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here